Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

127.43
Delayed Data
As of Jul 31
 +1.97 / +1.57%
Today’s Change
52.35
Today|||52-Week Range
140.00
+31.37%
Year-to-Date

Today’s Trading

Previous close125.46
Today’s open126.55
Day’s range124.82 - 130.00
Volume414,275
Average volume (3 months)769,017
Market cap$10.7B
Dividend yield--
Data as of 3:59pm ET, 07/31/2015

Growth & Valuation

Earnings growth (last year)-234.48%
Earnings growth (this year)+37.70%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+7.20%
P/E ratioNM
Price/Sales142.50
Price/Book10.51

Competitors

 Today’s
change
Today’s
% change
QQuintiles Transnatio...-2.03-2.58%
ISISIsis Pharmaceuticals...+1.76+3.31%
ICLRICON PLC-0.06-0.07%
PRXLPAREXEL Internationa...+0.28+0.41%
Data as of 4:04pm ET, 07/31/2015

Financials

Next reporting dateAugust 7, 2015
EPS forecast (this quarter)-$0.74
Annual revenue (last year)$50.6M
Annual profit (last year)-$360.4M
Net profit margin-712.79%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President &
Chief Operating Officer
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts